{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:53:50Z","timestamp":1790906030638,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00793-2","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:11:52Z","timestamp":1783501912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review of the cost-utility of dapagliflozin for managing chronic kidney disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Ronald","family":"Watema-Lord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjeev","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"793_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7\u201311.","journal-title":"Kidney Int Suppl"},{"key":"793_CR2","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12:e382\u201395.","journal-title":"Lancet Glob Health"},{"key":"793_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2471\/BLT.17.206441","volume":"96","author":"VA Luyckx","year":"2018","unstructured":"Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96:414\u2013D422.","journal-title":"Bull World Health Organ"},{"key":"793_CR4","doi-asserted-by":"publisher","first-page":"e074216","DOI":"10.1136\/bmj-2022-074216","volume":"383","author":"TK Chen","year":"2023","unstructured":"Chen TK, Hoenig MP, Nitsch D, et al. Advances in the management of chronic kidney disease. BMJ. 2023;383:e074216.","journal-title":"BMJ"},{"key":"793_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495\u2013502.","journal-title":"Nat Rev Endocrinol"},{"key":"793_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/1871525714666151106121215","volume":"13","author":"SH Syed","year":"2015","unstructured":"Syed SH, Gosavi S, Shami W, et al. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015;13:105\u201312.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"793_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(21)01242-3","volume":"398","author":"TH Jafar","year":"2021","unstructured":"Jafar TH. FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? Lancet Lond Engl. 2021;398:283\u20134.","journal-title":"Lancet Lond Engl"},{"key":"793_CR8","first-page":"274","volume":"35","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2020;35:274\u201382.","journal-title":"Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"793_CR9","unstructured":"Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015."},{"key":"793_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"793_CR11","unstructured":"O\u2019Connor D, Green S, Higgins JPT, editors. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, editors. Cochrane handbook of systematic reviews of intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available from: Accessed 16 June 2025. https:\/\/www.handbook.cochrane.org"},{"key":"793_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","volume":"41","author":"C-F Chiou","year":"2003","unstructured":"Chiou C-F, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32\u201344.","journal-title":"Med Care"},{"key":"793_CR13","first-page":"53","volume":"9","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm JMCP. 2003;9:53\u201361.","journal-title":"J Manag Care Pharm JMCP"},{"key":"793_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022;25:3\u20139.","journal-title":"Value Health"},{"key":"793_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6:51\u20139.","journal-title":"Evid Policy"},{"key":"793_CR16","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","volume":"37","author":"RL Tisdale","year":"2022","unstructured":"Tisdale RL, Cusick MM, Aluri KZ, et al. Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. J Gen Intern Med. 2022;37:3380\u20137.","journal-title":"J Gen Intern Med"},{"key":"793_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-021-02037-6","volume":"39","author":"K Vareesangthip","year":"2022","unstructured":"Vareesangthip K, Deerochanawong C, Thongsuk D, et al. Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Adv Ther. 2022;39:1279\u201392.","journal-title":"Adv Ther"},{"key":"793_CR18","first-page":"2021","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, et al. Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. Circ J Off J Jpn Circ Soc. 2022;86:2021\u20138.","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"793_CR19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, et al. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol CJASN. 2022;17:1730\u201341.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"793_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/13696998.2023.2174749","volume":"26","author":"A Swidan","year":"2023","unstructured":"Swidan A, Elsisi GH, Ibrahim MM, et al. Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait. J Med Econ. 2023;26:271\u201382.","journal-title":"J Med Econ"},{"key":"793_CR21","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1111\/dom.15201","volume":"25","author":"B-N Nguyen","year":"2023","unstructured":"Nguyen B-N, Mital S, Bugden S, et al. Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes. Diabetes Obes Metab. 2023;25:3030\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"793_CR22","doi-asserted-by":"publisher","first-page":"sfae025","DOI":"10.1093\/ckj\/sfae025","volume":"17","author":"P McEwan","year":"2024","unstructured":"McEwan P, Davis JA, Gabb PD, et al. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J. 2024;17:sfae025.","journal-title":"Clin Kidney J"},{"key":"793_CR23","doi-asserted-by":"publisher","first-page":"e0296067","DOI":"10.1371\/journal.pone.0296067","volume":"19","author":"SK Lim","year":"2024","unstructured":"Lim SK, Lee SWH. Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLoS ONE. 2024;19:e0296067.","journal-title":"PLoS ONE"},{"key":"793_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An introduction to Markov Modelling for economic evaluation. PharmacoEconomics. 1998;13:397\u2013409.","journal-title":"PharmacoEconomics"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00793-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:02:31Z","timestamp":1790902951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00793-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00793-2","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication (from patients\/participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}